Piramal Pharma Ltd Stock Price Today (NSE: PPLPHARMA)

Piramal Pharma Ltd

195.611.11 (0.56%)
Market Closed

Fundamental Score

...

Piramal Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Piramal Pharma Ltd share price today is 195.61, down 0.56% on NSE/BSE as of 31 July 2026. Piramal Pharma Ltd (PPLPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 22.85K (Cr). The 52-week high for PPLPHARMA share price is 209.44 and the 52-week low is 132.30. The company has a Return on Equity (ROE) of -3.83% and a debt-to-equity ratio of 0.70.

Piramal Pharma Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
202.26
Low
166.11
Volume
91.1L
Change
+16.06%

Piramal Pharma Ltd share price chart: 16.06% return over the past month. 52-week high ₹209.44, 52-week low ₹132.30.

Piramal Pharma Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
198.06200.80193.19195.6165.97L (Cr)
194.99202.26192.60196.72221.70L (Cr)
194.45201.00193.20195.68118.40L (Cr)
191.75194.46187.90193.4371.71L (Cr)
180.75192.64180.75192.05151.55L (Cr)
179.00185.79174.45184.8198.96L (Cr)
180.00182.00175.10178.8741.98L (Cr)
175.90181.60172.10179.4267.00L (Cr)
172.40178.12172.19174.7947.50L (Cr)
173.63174.77171.01171.9327.17L (Cr)

Piramal Pharma Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
168.68202.26166.11195.61+15.97%
172.99175.95158.10168.09-2.83%
161.87196.44157.77172.79+6.75%
140.00171.65136.26161.87+15.62%
152.62160.54132.30136.54-10.54%
152.40169.54149.76156.13+2.45%
172.75185.04148.31154.68-10.46%
187.90189.20165.12172.21-8.35%
199.76209.25184.20187.21-6.28%
191.07206.60190.52199.63+4.48%
183.45209.44182.00191.16+4.20%
198.00198.00182.80183.44-7.35%

AI Research Briefing

Powered by Gemini · 2026-04-10

Turnaround story trading at a premium; execution risk is high.

Research Confidence
6.0/10Moderate
TURNAROUNDBreakdown. 1M: -7.39%, 3M: -0.99%, 6M: -10.23%.P/E Nonex vs Industry P/E of 31.77x. Expensive given current losses.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Piramal Pharma completed the acquisition of Kenalog® from Bristol-Myers Squibb on April 1, 2026. Q3 FY26 results (ended December 31, 2025) showed a net loss of , a significant YoY decline. Revenue was down 3% YoY due to inventory destocking and slower order inflows in the CDMO business. However, the company is seeing early recovery signs with increased RFPs and order inflows.

CORE STORY (THE REAL GAME)

Piramal Pharma is a play on the Indian pharma industry's shift towards innovation and complex generics, rather than just a generics manufacturer. The market is trying to figure out if they can successfully pivot to higher-margin, higher-complexity products and services.

Why Now
  • Early signs of recovery in CDMO order inflows
  • Strong growth in consumer healthcare segment
  • Acquisition of Kenalog completed
Potential Catalysts
  • Sustained recovery in CDMO business
  • Successful integration of Kenalog
  • New product launches in consumer healthcare
Key Risks
  • High debt/equity ratio of 0.6
  • Low-interest coverage ratio of 1.52x
  • Negative free cash flow over 5 years
Institutional Activity

FII decreased by 0.59%, DII increased by 0.64%. Mixed signals suggest uncertainty.

Macro Context

Indian pharma industry projected to reach $130 billion by 2030, but faces global pricing pressures and trade uncertainties.

Cash Flow Quality

No. Free Cash Flow 5Y: ₹-29.18 Cr

3–6 Month Outlook

Piramal Pharma needs to demonstrate a sustained recovery in its CDMO business and successfully integrate the Kenalog acquisition to justify its valuation. Watch for Q4 results and management commentary on the CDMO pipeline.

Primary Thesis Risk

Failure to revive CDMO business and manage debt.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

-3.83%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

2.52%

Returns generated on total capital deployed

Good

Oper. Profit Margin (5Y Avg)

12.91%

Average operating profit margin over 5 years

Dividend Yield

0.08%

Annual dividend as % of current share price

Piramal Pharma Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

34.86%

% shares held by company founders/management

Excellent

FII Holding

30.17%

% shares held by foreign institutional investors

Good

DII Holding

15.61%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-25.01%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-0.08%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

7.03%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.70x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

0.99x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

751.45 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Piramal Pharma Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of PPLPHARMA across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Strong Cash Generation (₹751.45 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Strong Institutional Confidence (FII+DII: 45.78%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Below-Average Return on Equity (-3.83%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (2.52%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Profit Decline Concern (-25.01%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Weak Interest Coverage (0.99x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Piramal Pharma Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Piramal Pharma Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
8.2/100
196
₹22851.27
-3.83%
Poor
2.52%
Poor
0.7
Good
7.03%
Good
0.08%
66.4/100
1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
56.3/100
8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
51.4/100
5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA500087
40.2/100
1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
74.1/100
1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN500257
83.4/100
2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
61.5/100
2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
41/100
1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
24.6/100
1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
34.1/100
1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

Piramal Pharma Ltd PE Ratio History

Historical price-to-earnings ratio for PPLPHARMA — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20250.68₹172.21253.3x
FY 20240.14₹266.251901.8x
FY 20223.09₹111.9636.2x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Piramal Pharma Ltd Dividend History

Annual cash dividends paid by PPLPHARMA — dividend yield 0.08%

Financial YearDividends Paid (₹ Cr)
FY 202514.47 Cr
FY 202367.00 Cr
FY 202250.00 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Piramal Pharma Ltd Quarterly Performance

Latest quarterly metrics for PPLPHARMA — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-0.08%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-25.01%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

7.03%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Piramal Pharma Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for PPLPHARMA — calculated from daily price history

71RSI 14
Overbought — RSI 71

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
173
▲ Price above SMA 50 — Short-term bullish
SMA 200
171
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
10820K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Piramal Pharma Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Piramal Pharma Ltd (PPLPHARMA) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Piramal Pharma Ltd

About PPLPHARMA (Piramal Pharma Ltd)

Piramal Pharma Ltd is a dynamic force within the global pharmaceutical landscape, carving a niche as an integrated solutions provider. From its strategic base in India, the company... orchestrates a multifaceted approach encompassing research, development, and the manufacturing of both active pharmaceutical ingredients (APIs) and finished dosage forms. PPLPHARMA distinguishes itself through a commitment to innovation, evident in its pursuit of novel drug delivery systems and specialized formulations designed to address unmet medical needs. This commitment extends beyond its own product portfolio, as PPLPHARMA actively engages in collaborative partnerships with pharmaceutical companies worldwide, leveraging its expertise and infrastructure to accelerate the advancement of promising therapeutic candidates. Through a relentless focus on quality and efficiency, the company is positioned as a trusted partner in the ever-evolving world of healthcare. The company's operational model is built upon a foundation of advanced manufacturing capabilities and stringent regulatory compliance. With a network of state-of-the-art facilities strategically located across various geographies, Piramal Pharma Ltd offers a seamless, end-to-end solution for pharmaceutical companies seeking to outsource key stages of their drug development and manufacturing processes. This comprehensive offering spans from early-stage research and development to late-stage commercial production, ensuring that clients receive tailored support every step of the way. PPLPHARMA emphasizes sustainability in its operations, reflecting a commitment to responsible manufacturing practices and environmental stewardship. This holistic approach, combined with its unwavering focus on customer satisfaction, solidifies the company's reputation as a reliable and ethical partner within the industry. Beyond its core contract development and manufacturing (CDMO) services, Piramal Pharma Ltd also maintains a growing portfolio of proprietary pharmaceutical products targeting specific therapeutic areas. These branded offerings are distributed through a robust global network, enabling the company to directly impact patient outcomes and improve healthcare access. PPLPHARMA’s dedication to innovation and quality is underscored by its ongoing investment in research and development, constantly exploring new avenues for therapeutic advancement and operational efficiency. The company’s forward-looking vision positions it as a key player in shaping the future of pharmaceutical manufacturing and healthcare delivery, driven by a commitment to excellence and a passion for improving lives worldwide.

Company Details

Symbol:PPLPHARMA
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Ms. Nandini Ajay Piramal
Executive Chairperson
Mr. Vivek Valsaraj
CFO & Executive Director
Mr. Peter Daniel DeYoung
CEO of Piramal Global Pharma & Director

PPLPHARMA Share Price: Frequently Asked Questions

What is the current share price of Piramal Pharma Ltd?

Piramal Pharma Ltd (PPLPHARMA) trades at ₹195.61 on NSE and BSE. Market cap ₹22.85K (Cr). Educational data only.

What is the P/E ratio of Piramal Pharma Ltd?

Piramal Pharma Ltd has a P/E of N/Ax vs industry average 34.89x.

What is the Bull Run score for Piramal Pharma Ltd?

Piramal Pharma Ltd has a Bull Run score of 8.2/100 based on 25+ financial parameters.

Does Piramal Pharma Ltd pay dividends?

Piramal Pharma Ltd has a dividend yield of 0.08%. Past dividends don't guarantee future payments.

What is the ROE of Piramal Pharma Ltd?

Piramal Pharma Ltd has ROE of -3.83%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Piramal Pharma Ltd?

Piramal Pharma Ltd has debt-to-equity of 0.70.

Is Piramal Pharma Ltd a good investment?

Bull Run gives Piramal Pharma Ltd a score of 8.2/100. This is not investment advice — consult a SEBI-registered advisor.